Pricing Log in Create free account

DBV Technologies S.A. (DBVT) vs Nuvectis Pharma, Inc. (NVCT)

DBV Technologies S.A. and Nuvectis Pharma, Inc. are both Biotechnology companies. DBV Technologies S.A. and Nuvectis Pharma, Inc. are of similar size ($746.5M and $722.2M). Nuvectis Pharma, Inc. has the higher net margin (0.00% vs −5,547.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Nuvectis Pharma, Inc. leads on 11 and DBV Technologies S.A. on 1.

Valuation

Metric DBVT NVCT Biotechnology median
P/E n/m n/m 11.58
P/S 286.84 n/m 9.61
P/B 7.21 4.90 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 242.54 n/m 9.43
Earnings yield (26.00%) (8.97%) (32.28%)
Free cash flow yield (17.89%) (6.49%) (22.27%)

Profitability

Metric DBVT NVCT Biotechnology median
Gross margin 100.00% — 68.81%
Operating margin (5,571.63%) 0.00% 0.00%
Net margin (5,547.30%) 0.00% 0.00%
Free cash flow margin (5,131.50%) 0.00% 0.00%
Return on equity (205.75%) (66.98%) (50.30%)
Return on assets (127.19%) (57.20%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DBVT NVCT Biotechnology median
Revenue growth (TTM) (33.42%) — 6.78%
EPS growth (last fiscal year) 10.26% (18.92%) 29.88%
Revenue growth, 5-year CAGR (12.95%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DBVT NVCT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.24 9.92 4.74
Net debt to EBITDA 1.35 1.15 1.01

Dividend

Metric DBVT NVCT Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric DBVT NVCT Biotechnology median
Market cap 746.54m 722.17m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack